Abivax
Announced 24 Jul 2026$920.0M · Biotechnology · France
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.